Tamoxifen: A review of drug development for use in breast cancer and ocular adverse reactions
1 May 2003
Volume 04, Issue 2
The development of tamoxifen - from the early laboratory studies to the present-day use.
Background
The ideal treatment in any type of cancer is curative. Unfortunately, this is not yet an achievable goal with breast cancer. Therefore, the available treatment should aim to prolong life without diminishing the quality of life. Tamoxifen has been the most widely used endocrine therapy in the past 30 years for the treatment of metastatic breast cancer (Buzdar 2001). The incidence of side effects is low but ocular adverse reactions (OARs) have been regularly reported for this drug. The aim of this review is to look briefly at the development of tamoxifen from the early laboratory studies to the present-day use in treatment of breast cancer. The OARs associated with tamoxifen will be discussed and related to the clinical findings in practice. New drugs in development for the endocrine treatment of the disease will be briefly compared to tamoxifen.
Sign in to view the article
Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
Like many healthcare bodies and charities, we have become increasingly concerned
about the continued rise in harmful and misleading content on X and its growing
incompatibility with our values. Alongside a decline in meaningful engagement from our members on this platform, we have made the decision to stop posting content on X.
Many people across the UK are already suffering with hay fever season symptoms, with hay fever season now starting as early as February and March*.
In this guest column, Kevin Gutsell, President of ABDO, reflects on how closely aligned the professions have become – and must continue to be – as the eye care landscape evolves.